Literature DB >> 29365344

Dystrophinopathy muscle biopsies in the genetic testing ERA: One center's data.

Courtney R Carlson1, Steven A Moore2, Katherine D Mathews3.   

Abstract

INTRODUCTION: Comprehensive genetic testing for dystrophinopathy can detect ∼95% of pathogenic variants in the dystrophin gene (DMD) and is often the preferred diagnostic approach.
METHODS: We reviewed pathology reports for muscle biopsies evaluated at the University of Iowa with a pathological diagnosis of dystrophinopathy based on dystrophic histopathology and abnormal immunofluorescence staining: reduced to absent dystrophin, expression of utrophin, and loss of neuronal nitric oxide synthase.
RESULTS: The percentage of muscle biopsies with dystrophinopathy has been stable since 1997. Among 2,298 biopsies evaluated between 2011 and 2016, 72 (3.1%) had pathologic features of dystrophinopathy. Median age at biopsy was 8 years (range, 0.66-84). Half had undergone DMD genetic testing prior to biopsy. Clinical phenotypes recorded on requisitions were typical of muscular dystrophy for 57 (79%) biopsies. DISCUSSION: Muscle biopsy continues to play an important role in the diagnosis of dystrophinopathy, particularly in patients with later symptom onset, comorbidities, or normal DMD genetic testing results. Muscle Nerve, 2018.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Duchenne-Becker muscular dystrophy; diagnosis; dystrophinopathy; indication; muscle biopsy; pathology

Year:  2018        PMID: 29365344      PMCID: PMC6057846          DOI: 10.1002/mus.26083

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  14 in total

1.  Evidence-based guideline summary: diagnosis and treatment of limb-girdle and distal dystrophies: report of the guideline development subcommittee of the American Academy of Neurology and the practice issues review panel of the American Association of Neuromuscular & Electrodiagnostic Medicine.

Authors:  Pushpa Narayanaswami; Michael Weiss; Duygu Selcen; William David; Elizabeth Raynor; Gregory Carter; Matthew Wicklund; Richard J Barohn; Erik Ensrud; Robert C Griggs; Gary Gronseth; Anthony A Amato
Journal:  Neurology       Date:  2014-10-14       Impact factor: 9.910

2.  Prevalence of Duchenne and Becker muscular dystrophies in the United States.

Authors:  Paul A Romitti; Yong Zhu; Soman Puzhankara; Katherine A James; Sarah K Nabukera; Gideon K D Zamba; Emma Ciafaloni; Christopher Cunniff; Charlotte M Druschel; Katherine D Mathews; Dennis J Matthews; F John Meaney; Jennifer G Andrews; Kristin M Caspers Conway; Deborah J Fox; Natalie Street; Melissa M Adams; Julie Bolen
Journal:  Pediatrics       Date:  2015-02-16       Impact factor: 7.124

Review 3.  Progressive muscular dystrophies.

Authors:  Jamel Chelly; Isabelle Desguerre
Journal:  Handb Clin Neurol       Date:  2013

4.  The frequency of patients with dystrophin abnormalities in a limb-girdle patient population.

Authors:  E Arikawa; E P Hoffman; M Kaido; I Nonaka; H Sugita; K Arahata
Journal:  Neurology       Date:  1991-09       Impact factor: 9.910

5.  Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort.

Authors:  Kevin M Flanigan; Diane M Dunn; Andrew von Niederhausern; Payam Soltanzadeh; Eduard Gappmaier; Michael T Howard; Jacinda B Sampson; Jerry R Mendell; Cheryl Wall; Wendy M King; Alan Pestronk; Julaine M Florence; Anne M Connolly; Katherine D Mathews; Carrie M Stephan; Karla S Laubenthal; Brenda L Wong; Paula J Morehart; Amy Meyer; Richard S Finkel; Carsten G Bonnemann; Livija Medne; John W Day; Joline C Dalton; Marcia K Margolis; Veronica J Hinton; Robert B Weiss
Journal:  Hum Mutat       Date:  2009-12       Impact factor: 4.878

Review 6.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.

Authors:  Katharine Bushby; Richard Finkel; David J Birnkrant; Laura E Case; Paula R Clemens; Linda Cripe; Ajay Kaul; Kathi Kinnett; Craig McDonald; Shree Pandya; James Poysky; Frederic Shapiro; Jean Tomezsko; Carolyn Constantin
Journal:  Lancet Neurol       Date:  2009-11-27       Impact factor: 44.182

7.  Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet).

Authors:  Emma Ciafaloni; Deborah J Fox; Shree Pandya; Christina P Westfield; Soman Puzhankara; Paul A Romitti; Katherine D Mathews; Timothy M Miller; Dennis J Matthews; Lisa A Miller; Christopher Cunniff; Charlotte M Druschel; Richard T Moxley
Journal:  J Pediatr       Date:  2009-04-25       Impact factor: 4.406

8.  Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase.

Authors:  Sylvie Tuffery-Giraud; Christophe Béroud; France Leturcq; Rabah Ben Yaou; Dalil Hamroun; Laurence Michel-Calemard; Marie-Pierre Moizard; Rafaëlle Bernard; Mireille Cossée; Pierre Boisseau; Martine Blayau; Isabelle Creveaux; Anne Guiochon-Mantel; Bérengère de Martinville; Christophe Philippe; Nicole Monnier; Eric Bieth; Philippe Khau Van Kien; François-Olivier Desmet; Véronique Humbertclaude; Jean-Claude Kaplan; Jamel Chelly; Mireille Claustres
Journal:  Hum Mutat       Date:  2009-06       Impact factor: 4.878

9.  An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus.

Authors:  A P Monaco; C J Bertelson; S Liechti-Gallati; H Moser; L M Kunkel
Journal:  Genomics       Date:  1988-01       Impact factor: 5.736

Review 10.  The importance of genetic diagnosis for Duchenne muscular dystrophy.

Authors:  Annemieke Aartsma-Rus; Ieke B Ginjaar; Kate Bushby
Journal:  J Med Genet       Date:  2016-01-11       Impact factor: 6.318

View more
  1 in total

Review 1.  What Every Neuropathologist Needs to Know: The Muscle Biopsy.

Authors:  James S Nix; Steven A Moore
Journal:  J Neuropathol Exp Neurol       Date:  2020-07-01       Impact factor: 3.685

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.